Mechanisms of Action for Surgical Alternative Drugs and How to Manage Them
May 10th 2022In the world of medical oncologist Ann W. Silk, MD, MS a 30% response rate can be good news. So can drugs that can limit side effects to address a discontinuation rate that may be as high as 30%. Silk discusses the mechanisms of action of existing and new tools, such as immunotherapy, and recommendations for how physicians can maximize their effectiveness in a clinical setting.
Factors That Determine When Surgery Is—or Is Not--an Option
May 10th 2022Chrysalyne D. Schmults, MD, provides talking points on assessing which patients are ideal candidates for surgery and, when surgery is not an option, matching medications to the needs and quality of life concerns for the individual patient. She offers best-practice guidance for optimizing treatment choices that address challenges surrounding extended durability, reduction of adverse effects, and improvement in rates of occurrence of progression.
Emerging and Established Nonsurgical Treatment Options
May 10th 2022Darrell S. Rigel, MD, talks through the pros, cons, and unknowns of established medications such as Hedgehog inhibitors and newly FDA-approved drugs such as cemiplimab (Libtayo; Sanofi and Regeneron Pharmaceuticals). Get the latest on dosing, drug holidays, tolerability, and long-term disease management.
Staging, Treatment Plans and Building a Tumor Board
May 10th 2022What risks do patients with the highest stage advanced BCC have for metastasis or death? Chrysalyne D. Schmults, MD, and her team at Brigham and Women’s Hospital in Boston, Massachusetts, developed a new staging system to help answer that question. Here, she shares insights on tumor classification, its implication for treatment, and the ground rules for creating an effective tumor review board.
From Diagnosis to Development of a Multidisciplinary Team
May 10th 2022By the time patients present to Darrell S. Rigel, MD, with advanced basal cell carcinoma (BCC), their lesions are likely to be too large or too numerous to be curable with a simple surgical solution. “You get to a point where there are just positive margins or the lesion is so large that it’s going to require inpatient treatment,” he says. “Because of the complexity, it’s important to build a multidisciplinary team to assess the patient, create a treatment plan, and optimize ongoing management.” Find out how to build a strong team and what each member can contribute.
Comments on the Epsolay FDA Approval for Rosacea
May 2nd 2022Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.
NP Review: Clinical Implications of Atopic Dermatitis
April 24th 2022In this video interview, Andrew Blauvelt, MD, MBA, dives into the current state of atopic dermatitis treatment from his talk presented at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.
NP Review: Clinical Implications of Psoriasis
April 23rd 2022In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.